Experimental Medicine INitiative to Explore New Therapies

重要的是，这一举措将侧重于与GSK建立现有合作伙伴关系的学术中心，并有证据表明与GSK建立了富有成效的工作关系，以确保建立一个灵活、反应迅速的网络。这将有助于以及时和具有成本效益的方式快速实施和成功交付项目。每个核心中心还拥有一个成熟的生物医学研究中心（或其苏格兰等同机构），并将在疾病领域提供互补的专业知识，这些领域可以充分利用英国GSK积极的研发成果，即：免疫炎症、炎症性疾病和纤维化。各参与中心的密切配合将促进机构间联盟的形成，参与该网络的前提是愿意合作和分享学术专长和资源，并有可能接触到更多的患者群体。所有合作伙伴还致力于确保每个项目都有培训元素，以培养下一代灵活的研究人员，他们能够跨界并在学术和行业环境中工作。项目计划将由学术和GSK研究人员共同制定。该计划成功的关键在于GSK的前期承诺，即提供独特的靶点和药物发现专业知识、现有的许可药物和临床可用化合物，以及最先进的平台技术。所有的临床研究都将由GSK完全赞助，从而使该网络能够从其全面的运营、监管、分析和统计能力中受益。重要的是，该网络将只关注目前不在GSK组合活动范围内的项目，尽管它们可能代表未来药物开发机会的来源。在GSK产品组合目前的重点之外，加强对高度未满足需求疾病的了解？参与机构之间的合作，以提供最好的科学？里程碑驱动的方法来进行精心设计的实验医学项目，以增加对人类疾病的基本机制的理解？匹配MRC和GSK，在实物，资金，建设专业知识和基础设施在英国？学术合作伙伴与GSK之间的培训和知识与技能交流？数据的及时发布本文件概述了EMINENT的愿景、拟议的工作程序、治理和预期成果，以及一系列说明性的示范项目，以展示这一举措的潜在价值和影响。

new targets and approaches and tools for the evaluation of diseases for which pharmaceuticalinterest has traditionally been low.Importantly, this initiative will focus on academic centres with existing partnerships and evidence ofa productive working relationship with GSK to ensure an agile and responsive network. This willallow both rapid implementation and the successful delivery of projects in a timely and costeffectivemanner. Each of the core centres also has an established Biomedical Research Centre (or itsScottish equivalent), and will provide complementary expertise in disease areas that can take fulladvantage of the active UK-based GSK R&D effort, namely: immuno-inflammation, respiratorydisease, and fibrosis. The close alignment of the participating centres will foster the formation ofinter-institutional alliances and participation in the Network is predicated on a willingness tocollaborate and share academic expertise and resource, with the potential to access larger patientcohorts. All partners are also committed to ensuring that there is a training element within eachproject in order to develop the next generation of researchers who are flexible and able to crossboundaries and work in both the academic and industry environments.Projects plans will be developed jointly by the academic and GSK investigators. Vital to the success ofthe initiative is the up-front commitment GSK has made to providing unique target and drugdiscovery expertise, existing licensed drugs and clinic-ready compounds, and access to state-of-theart platform technologies. All clinical studies will be fully sponsored by GSK, thereby allowing theNetwork to benefit from its full operational, regulatory, analytical and statistical capabilities.Importantly, the Network will focus solely on projects which currently sit outside GSK’s portfolioactivities, although they could potentially represent a source of future drug developmentopportunities.Hence the key principles of the EMINENT initiative are:? Enhancing disease understanding in diseases of high unmet need, outside the current focus ofthe GSK portfolio? Collaboration across participating institutions to deliver the best science? Milestone-driven approach to conduct well designed experimental medicine projects to increaseunderstanding of the fundamental mechanisms of human disease? Matched MRC and GSK, in-kind, funding, building expertise and infrastructure in the UK? Training and the exchange of knowledge and skills between academic partners and GSK? Prompt publication of dataThis document outlines the vision, proposed working procedures, governance, and expectedoutcomes of EMINENT, together with a selection of illustrative, exemplar projects to showcase thepotential value and impact of this initiative.